TBCRC 041 Randomized Phase II Trial to Evaluate Alisertib Alone or Combined with Fulvestrant in Women with Advanced, Hormone-Receptor Positive (HR+) Breast Cancer
Clinical Trial Grant
Administered By
Duke Cancer Institute
Awarded By
Mayo Clinic
Start Date
March 20, 2019
End Date
October 2, 2024
Administered By
Duke Cancer Institute
Awarded By
Mayo Clinic
Start Date
March 20, 2019
End Date
October 2, 2024